Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
Systematic review published in International journal of clinical pharmacy (2021)
Abstract
Background Argatroban, lepirudin, desirudin, bivalirudin, and danaparoid are commonly used to manage heparin-induced thrombocytopenia related complications. However, the most suitable drug for this condition still remains controversial. Aim of the review This Bayesian network meta-analysis study compared the most common anticoagulant drugs used in the management of heparin-induced thrombocytopenia. Method All clinical trials comparing two or more anticoagulant therapies for suspected or confirmed heparin-induced thrombocytopenia were considered for inclusion. Studies concerning the use of heparins or oral anticoagulants were not considered. Data concerning hospitalisation length, thromboembolic, major, and minor haemorrhagic events, and mortality rate were collected. The network analyses were made through the STATA routine for Bayesian hierarchical random-effects model analysis with standardised mean difference (SMD) and log odd ratio (LOR) effect measures. Results Data from a total of 4338 patients were analysed. The overall mean age was 62.31 ± 6.6 years old. Hospitalization length was considerably shorter in favour of the argatroban group (SMD: - 1.70). Argatroban evidenced the lowest rate of major (LOR: - 1.51) and minor (LOR: - 0.57) haemorrhagic events. Argatroban demonstrated the lowest rate of thromboembolic events (LOR: 0.62), and mortality rate (LOR: - 1.16). Conclusion Argatroban performed better overall for selected patients with HIT. Argatroban demonstrated the shortest hospitalization, and lowest rate of haemorrhages, thromboembolisms, and mortality compared to bivalirudin, lepirudin, desirudin, and danaparoid.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis.
Por qué esto importa para la hirudoterapia
Este metanálisis en red bayesiano agrupó datos de 4.338 pacientes para comparar cinco anticoagulantes —argatrobán, lepirudina, desirudina, bivalirudina y danaparoide— para el manejo de la trombocitopenia inducida por heparina, concluyendo que el argatrobán tuvo un mejor desempeño global, con menor duración de la hospitalización y menores tasas de eventos hemorrágicos, tromboembolismo y mortalidad. El trabajo tiene relevancia clara para la hirudoterapia porque la lepirudina y la desirudina son derivados recombinantes de la hirudina (el anticoagulante de la saliva de la sanguijuela medicinal) y la bivalirudina es un análogo basado en hirudina, de modo que el análisis proporciona un contexto de efectividad comparativa para las terapias derivadas de hirudina frente a un agente no derivado de hirudina. Una advertencia importante es que el metanálisis en red se basa en comparaciones indirectas entre ensayos heterogéneos más que en evidencia directa de comparaciones cabeza a cabeza aleatorizadas, y el estudio se refiere al manejo farmacológico anticoagulante de la TIH y no a la terapia con sanguijuelas en sí.
Citación
Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
Colarossi G et al. · International journal of clinical pharmacy, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026